Compare Dominion Energy Inc (D) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dominion Energy Inc vs Novo Nordisk A/S — how do they compare? Dominion Energy Inc trades at $61.71 (market cap $54.31B), while Novo Nordisk A/S trades at $38.16 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 3× Dominion Energy Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Dominion Energy Inc for 76 Days and Novo Nordisk A/S for 116 Days on average.
| D | NVO | |
|---|---|---|
Market Cap | $54.31B | $165.31B |
Volume | 6,944,775 | 11,432,838 |
Sector | Utilities | Health |
52-Week High | $71.67 | $63.98 |
52-Week Low | $57.08 | $35.29 |
Typical Hold Time | 76 Days | 116 Days |
Enterprise Value | $108.43B | $179.56B |
Dividend Yield | 4.32% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $61.53, down 0.76% on the day, with a bearish technical signal driven by moving averages and ADX. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains solid profitability with a net income margin of 13.99%. Recent news highlights a proposed merger with NextEra Energy, which could reshape its strategic direction.
The stock offers a consensus price target of $71.56, implying potential upside, supported by a dividend yield. Key risks include execution of the merger, high debt levels, and interest rate sensitivity. Analyst sentiment is mixed with a Hold majority, reflecting cautious optimism amid transformative corporate actions.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
